These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2107012)

  • 1. Three-monthly GnRH agonist (buserelin) for prostatic cancer.
    Waxman J; Sandow J; Abel P; Barton C; Keane P; Williams G
    Br J Urol; 1990 Jan; 65(1):43-5. PubMed ID: 2107012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
    Waxman J; Sandow J; Thomas H; James N; Williams G
    Cancer Chemother Pharmacol; 1989; 25(3):219-20. PubMed ID: 2513141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
    Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
    Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
    Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI; Falkson G; Falkson HC
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J
    Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.